Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19417541 | ACACIA NILOTICA BASED HYDROGEL AND METHOD OF MAKING THE SAME | December 2025 | February 2026 | Allow | 2 | 0 | 0 | No | No |
| 19382964 | METHOD FOR MAKING METHANE FROM CARBON DIOXIDE | November 2025 | March 2026 | Allow | 4 | 0 | 0 | No | No |
| 19383003 | METHOD FOR MAKING A BENZIMIDAZOLE | November 2025 | March 2026 | Allow | 4 | 0 | 0 | No | No |
| 19376432 | ALBUMIN BINDING PROTEINS AND METHODS OF USE | October 2025 | February 2026 | Allow | 4 | 0 | 0 | Yes | No |
| 19375973 | FRAGMENTING RNA:DNA HYBRIDS | October 2025 | January 2026 | Allow | 3 | 0 | 0 | Yes | No |
| 19371517 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2025 | March 2026 | Allow | 4 | 0 | 0 | Yes | No |
| 19371529 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2025 | March 2026 | Allow | 5 | 0 | 0 | Yes | No |
| 19364654 | METHODS OF TREATING DISORDERS USING CSF1R INHIBITORS | October 2025 | February 2026 | Allow | 4 | 1 | 0 | No | No |
| 19364297 | FORMULATIONS OF ANTI-CD38 ANTIBODIES FOR SUBCUTANEOUS ADMINISTRATION | October 2025 | March 2026 | Allow | 4 | 0 | 0 | Yes | No |
| 19361770 | COMPOSITIONS AND METHODS FOR MOLECULAR LABELING | October 2025 | March 2026 | Allow | 5 | 1 | 0 | No | No |
| 19357447 | ANAPLASTIC LYMPHOMA KINASE (ALK) DEGRADERS AND USES THEREOF | October 2025 | January 2026 | Allow | 3 | 0 | 0 | No | No |
| 18831858 | Delosperma plant named 'Electric Slide' | October 2025 | January 2026 | Allow | 3 | 0 | 0 | No | No |
| 19355669 | MUSCLE-SPECIFIC EXPRESSION CASSETTES | October 2025 | March 2026 | Allow | 5 | 0 | 0 | No | No |
| 19352234 | SUBSTITUTED HETEROCYCLES AND USES THEREOF | October 2025 | December 2025 | Allow | 2 | 0 | 0 | No | No |
| 19352045 | BENZO NITROGEN-CONTAINING HETEROAROMATIC RING DERIVATIVE AND USE THEREOF IN MEDICINE | October 2025 | December 2025 | Allow | 2 | 0 | 0 | No | No |
| 19352098 | PD-L1 ANALOG FUSION PROTEINS FOR ANTIGEN SPECIFIC IMMUNOTHERAPY AND METHODS OF USE | October 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19350804 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | October 2025 | January 2026 | Allow | 3 | 1 | 0 | No | No |
| 19350928 | LIGAND DISCOVERY AND GENE DELIVERY VIA RETROVIRAL SURFACE DISPLAY | October 2025 | January 2026 | Allow | 3 | 1 | 0 | No | No |
| 19350944 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2025 | December 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19350939 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2025 | February 2026 | Allow | 5 | 0 | 0 | Yes | No |
| 19350933 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | October 2025 | February 2026 | Allow | 5 | 0 | 0 | Yes | No |
| 19350713 | ADVANTAGEOUS MORPHIC FORM OF AT-527 HEMI-SULFATE SALT | October 2025 | March 2026 | Abandon | 5 | 1 | 0 | No | No |
| 19347136 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | October 2025 | March 2026 | Allow | 5 | 1 | 1 | Yes | No |
| 19344588 | BRAND-NEW SKELETON 99MTC-FAPI DIAGNOSTIC PROBE AND USE THEREOF IN PREPARATION OF DRUG OR REAGENT FOR DIAGNOSING TUMORS | September 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19345445 | METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY | September 2025 | January 2026 | Allow | 3 | 1 | 0 | Yes | No |
| 19343371 | THERAPEUTIC COMPOSITIONS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS | September 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19340137 | SYNTHESIS AND COMPOSITION OF AMINO ACID LINKING GROUPS CONJUGATED TO COMPOUNDS USED FOR THE TARGETED IMAGING OF TUMORS | September 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19339250 | Intraoral Cleaning Tablet | September 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 19333265 | Stabilized Formulations Containing Anti-Interleukin-4 Receptor (IL-4R) Antibodies | September 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 18831815 | INTERSPECIFIC TREE Named 'Flavor Chief' | September 2025 | November 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19329790 | PETUNIA PLANT NAMED 'WNPETSVBG27' | September 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 18831801 | Miniature Rose Plant Named 'Poulpal097' | September 2025 | March 2026 | Allow | 6 | 1 | 0 | Yes | No |
| 18831797 | Hybrid Tea Rose Plant Named 'Poulpmt010' | September 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 18831799 | Miniature Rose Plant Named 'Poulpah 125' | September 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 19329242 | PHALAENOPSIS PLANT NAMED 'PHA329495' | September 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 18831805 | Miniature rose plant named 'Poulpar137' | September 2025 | February 2026 | Allow | 5 | 0 | 0 | No | No |
| 18831806 | Miniature Rose Plant Named 'Poulty038' | September 2025 | February 2026 | Allow | 5 | 0 | 0 | No | No |
| 18831808 | Miniature Rose Plant Named 'Poulty046' | September 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19327881 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | September 2025 | January 2026 | Allow | 4 | 1 | 0 | Yes | No |
| 19327867 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | September 2025 | March 2026 | Allow | 6 | 1 | 1 | Yes | No |
| 19328055 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | September 2025 | December 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19327711 | METHODS OF IMPROVING LUNG FUNCTION | September 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19327682 | METHODS OF IMPROVING LUNG FUNCTION | September 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19326225 | DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS | September 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19324663 | MARINE ORGANISM INFUSED EFFERVESCENT TABLET FOR PRODUCING ENHANCED SUSPENSIONS | September 2025 | January 2026 | Allow | 4 | 0 | 1 | Yes | No |
| 19324396 | MARINE ORGANISM DERIVED SURFACTANT | September 2025 | February 2026 | Allow | 5 | 0 | 1 | No | No |
| 19323422 | PHARMACEUTICAL COMPOSITION FOR KERATOSIS AND USE THEREOF | September 2025 | March 2026 | Allow | 6 | 0 | 1 | Yes | No |
| 19323694 | STIMULANT COMPOSITION AND PROCESS FOR MAKING SAME | September 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19323583 | COMPOSITION FOR REGULATING PRODUCTION OF INTERFERING RIBONUCLEIC ACID | September 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 18831789 | Allium Plant Named 'All The Buzz' | September 2025 | October 2025 | Allow | 1 | 0 | 0 | No | No |
| 18831788 | Epimedium plant named 'Jester's Hat' | September 2025 | November 2025 | Allow | 2 | 0 | 0 | No | No |
| 19322628 | CAPSID VARIANTS AND METHODS OF USING THE SAME | September 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19320604 | COMPOUNDS FOR TARGETED PROTEIN DEGRADATION | September 2025 | February 2026 | Allow | 5 | 1 | 1 | No | No |
| 19320567 | SHEPHERDIA PLANT NAMED 'TORREY' | September 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19320020 | CHEMICAL COMPOUNDS AND USES THEREOF | September 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19319209 | AQUEOUS COMPOSITION | September 2025 | February 2026 | Allow | 5 | 1 | 0 | Yes | No |
| 19319360 | CANNABINOID ANALOGS, FORMULATIONS, AND METHODS OF USE | September 2025 | January 2026 | Allow | 5 | 0 | 1 | Yes | No |
| 19318311 | METHODS FOR DETECTING INTERCELLULAR INTERACTIONS OF CELLS IN A COMPARTMENT OF A FLUIDIC DEVICE | September 2025 | January 2026 | Allow | 5 | 1 | 0 | Yes | No |
| 19318315 | METHODS FOR INCUBATING AND ANALYZING A CELL IN A COMPARTMENT OF A FLUIDIC DEVICE | September 2025 | January 2026 | Allow | 5 | 1 | 0 | Yes | No |
| 19317897 | METHOD FOR EXTRACTING UNFRACTIONATED HEPARIN FROM CAMEL INTESTINAL MUCOSA | September 2025 | January 2026 | Allow | 5 | 1 | 0 | No | No |
| 19316708 | SELF-REGULATING PHOTO-CURABLE COOLING HYDROGEL AND PREPARATION METHOD AND APPLICATION THEREOF | September 2025 | January 2026 | Allow | 4 | 0 | 1 | Yes | No |
| 19316633 | IL13 AND IL31 BISPECIFIC POLYPEPTIDES AND USES THEREOF | September 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 19316641 | EPIPREMNUM PLANT NAMED 'ETH' | September 2025 | November 2025 | Allow | 3 | 0 | 0 | No | No |
| 19317124 | Kalanchoe Plant Named 'KLEKB24054' | September 2025 | November 2025 | Allow | 2 | 0 | 0 | No | No |
| 19316629 | PHALAENOPSIS PLANT NAMED 'PHA569755' | September 2025 | November 2025 | Allow | 2 | 0 | 0 | No | No |
| 19315655 | Chamaecyparis Plant Named 'Edengra 23' | September 2025 | November 2025 | Allow | 2 | 0 | 0 | No | No |
| 19315583 | ANTHURIUM PLANT NAMED 'AN2244532' | August 2025 | October 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19315581 | ANTHURIUM PLANT NAMED 'AN2181990' | August 2025 | November 2025 | Allow | 3 | 0 | 0 | No | No |
| 19315587 | ANTHURIUM PLANT NAMED 'AN2541672' | August 2025 | November 2025 | Allow | 3 | 0 | 0 | No | No |
| 19315584 | ANTHURIUM PLANT NAMED 'AN2297549' | August 2025 | November 2025 | Allow | 2 | 0 | 0 | No | No |
| 19314145 | Euphorbia Plant Named 'Miner's Berry Bordeaux' | August 2025 | October 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19315079 | S-BETA-HYDROXYBUTYRATE ESTERS FOR IMPROVING METABOLIC FUNCTION | August 2025 | January 2026 | Allow | 5 | 1 | 0 | No | No |
| 19312645 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19312755 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19312786 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | January 2026 | Allow | 4 | 1 | 0 | No | No |
| 19313046 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19313010 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | February 2026 | Allow | 6 | 1 | 0 | No | No |
| 19312656 | CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR | August 2025 | December 2025 | Allow | 3 | 0 | 0 | No | No |
| 19313576 | MANDEVILLA PLANT NAMED 'TVMD944' | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19313647 | MANDEVILLA PLANT NAMED 'TVMD1232' | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19313635 | MANDEVILLA PLANT NAMED 'TVMD1143' | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19313539 | MANDEVILLA PLANT NAMED 'TVMD714' | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19313675 | MANDEVILLA PLANT NAMED 'TVMD1626' | August 2025 | December 2025 | Allow | 4 | 0 | 0 | No | No |
| 19313668 | MANDEVILLA PLANT NAMED 'TVMD1573' | August 2025 | November 2025 | Allow | 2 | 0 | 0 | No | No |
| 19313653 | MANDEVILLA PLANT NAMED 'TVMD1330' | August 2025 | November 2025 | Allow | 2 | 0 | 0 | No | No |
| 19313602 | MANDEVILLA PLANT NAMED 'TVMD982' | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19313620 | MANDEVILLA PLANT NAMED 'TVMD1037' | August 2025 | November 2025 | Allow | 3 | 0 | 0 | No | No |
| 19313568 | MANDEVILLA PLANT NAMED 'TVMD932' | August 2025 | November 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19312906 | HYDROXYPROPYL BETA-CYCLODEXTRIN COMPOSITIONS AND METHODS | August 2025 | February 2026 | Allow | 6 | 0 | 0 | Yes | No |
| 19311629 | UROLITHIN GUMMY (PECTIN) FORMULATIONS | August 2025 | February 2026 | Allow | 5 | 1 | 0 | No | No |
| 19311344 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | August 2025 | January 2026 | Allow | 5 | 1 | 1 | Yes | No |
| 19311988 | SYSTEMS AND METHODS TO DETECT RARE MUTATIONS AND COPY NUMBER VARIATION | August 2025 | March 2026 | Allow | 6 | 1 | 0 | No | No |
| 19309669 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | August 2025 | December 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 19310812 | REVERSE TRANSCRIPTASE VARIANTS | August 2025 | November 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19310785 | ROSA PLANT NAMED 'GEN R273' | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19310827 | PHALAENOPSIS PLANT NAMED 'FLORICHROME' | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19310781 | HYBRID TEA ROSE PLANT NAMED 'ESM R895' | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19309448 | 2-DIARYLMETHYL-4-AMINOTETRAHYDROPYRAN DERIVATIVES AND RELATED COMPOUNDS AS ANTICANCER, ANTIINFLAMMATORY, ANTIFIBROTIC AND NEUROPROTECTIVE AGENTS | August 2025 | November 2025 | Allow | 2 | 0 | 0 | Yes | No |
| 19308863 | RAS INHIBITORS | August 2025 | December 2025 | Allow | 4 | 1 | 0 | No | No |
| 19309246 | BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTION | August 2025 | March 2026 | Allow | 7 | 0 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for tech-center 1600.
With a 29.8% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Technology Center 1600 covers Biotechnology and Organic Chemistry. This technology center has examined 687,967 patent applications in our dataset, with an overall allowance rate of 60.0%. Applications typically reach final disposition in approximately 31 months.
Applications in Technology Center 1600 receive an average of 1.86 office actions before reaching final disposition. The median prosecution time is 31 months.
This technology center encompasses a broad range of technical subject matter. Prosecution strategies should be tailored based on the specific art unit and examiner assigned to your application. Review the group, art unit, and examiner-level statistics for more targeted strategic insights.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.